Study of an experimental drug vs. chemo for recurring uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (18 or older) with endometrial cancer that has returned.
- Your tumor has been tested and found to have a certain level of HER2 protein (1+, 2+, or 3+).
- Your cancer can be measured on scans (by RECIST rules).
- You have had chemotherapy with platinum before, and your cancer came back within 12 months of that treatment or after treatment for advanced disease.
- You have also had immunotherapy (a type of treatment that helps your immune system fight cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new investigational drug called Puxitatug Samrotecan (AZD8205) against standard chemotherapy in people whose endometrial cancer has come back or spread after prior treatment with platinum chemo and an immunotherapy. The goal is to see if the new drug works better.
This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.